Perrigo acquisition could threaten Mylan's investment grade

NEW YORK, April 10 (IFR) - Drugmaker Mylan is at risk of dropping back into junk territory if it doesn't strike a perfect balance between bond and equity to finance its proposed US$30bn acquisition of healthcare supplier Perrigo, analysts warned.